Ready to Jump After Recent Trade: Arcus Biosciences Inc (RCUS)

With 0.97 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.88 million shares. The 52-week range on RCUS shows that it touched its highest point at $19.69 and its lowest point at $9.85 during that stretch. It currently has a 1-year price target of $32.55. Beta for the stock currently stands at 1.45.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RCUS was down-trending over the past week, with a drop of -5.37%, but this was down by -24.88% over a month. Three-month performance dropped to -38.67% while six-month performance fell -44.09%. The stock lost -49.35% in the past year, while it has lost -34.92% so far this year. A look at the trailing 12-month EPS for RCUS yields -3.10 with Next year EPS estimates of -4.14. For the next quarter, that number is -1.04. This implies an EPS growth rate of -31.20% for this year and -0.50% for next year. EPS is expected to decline by -2.51% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -10.20%.

Float and Shares Shorts:

At present, 92.20 million RCUS shares are outstanding with a float of 58.49 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RCUS since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.61152 being high and -$4.15711 being low. For RCUS, this leads to a yearly average estimate of -$3.41096. Based on analyst estimates, the high estimate for the next quarter is -$0.89 and the low estimate is -$1.35. The average estimate for the next quarter is thus -$1.09.

Summary of Insider Activity:

Insiders traded RCUS stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.